Bionsight combines chemoproteomics with artificial intelligence to accelerate therapeutic target identification and validation. The platform decodes complex protein-ligand interactions to reveal novel mechanisms of action with high precision. This approach enables pharmaceutical companies to predict efficacy, profile safety, and optimize lead compounds faster in the drug discovery pipeline.
Funding
$5.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The drug discovery process is often slow and inefficient due to the complexity of biomedical data and the challenges in identifying and validating promising drug targets. Analyzing vast amounts of data from biomedical literature, assays, and chemical/gene profiles to pinpoint relevant targets and repurpose existing drugs remains a significant bottleneck.
Solution
Bionsight offers an AI-powered bioinformatics platform designed to accelerate and streamline drug discovery. The platform integrates biomedical databases and employs deep learning models to extract insights from complex data networks, simplifying the identification of potential drug targets and enabling drug repurposing. Bionsight's core technology includes three key components: Glance, a biomedical database platform; Skeleton, an AI research platform for drug candidate optimization; and Javelin, a chemoproteomics platform that analyzes high-resolution mass spectrometry data to discover biochemical interactions between drugs and protein targets. By combining these tools, Bionsight facilitates target identification, drug hit discovery, and novel drug design with increased precision and efficiency. The platform also supports AI-driven chemoproteomics target screening and natural substance discovery.
Target Audience
Bionsight's platform is designed for pharmaceutical companies, research institutions, and drug developers seeking to accelerate drug discovery, identify novel drug targets, and repurpose existing drugs.
Features
- Glance: Integrated biomedical database platform utilizing deep learning models for target identification and drug repurposing
- Skeleton: AI research platform for optimizing drug candidates with a large in-house database of compound fragments
- Javelin: Chemoproteomics platform analyzing high-resolution mass spectrometry data to discover drug-target interactions
- AI-driven chemoproteomics target screening for target or off-target identification
- AI-driven recommendation of natural substances with therapeutic benefits
- AI-driven novel drug discovery for specific protein targets
- AI-driven identification of small molecules with bioactivity for drug repositioning